Program
Torsemide
Also written as “Torasemide tablet 10 mg”, “torasemide” and “torsemide”.
Its studies are mostly in Heart Failure · Edema · Body Weight Changes · Hypertension · Diabetes Mellitus, Type 2, led by 5 companies.
Drug pageTorsemide: every studyMany companies study it; this page follows only the 11 they lead. All 23 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sarfez Pharmaceuticalsits history only | 40 open or running | phase 4since Nov 24, 2024 | Apr 17, 2018 | none ahead |
| Ferrer Internacionalits history only | 20 open or running | phase 4since Jun 6, 2006 | Jun 6, 2006 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Par Healthits history only | 20 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| Menarini Groupits history only | 11 open or running | phase 1since Sep 10, 2025 | Sep 10, 2025 | none ahead |
Also a collaborator on its studies: Anapharm.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hikma Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2008First studies: 2 no phase studies in EdemaFirst studyNCT00602615, NCT00602303
TargetBeta
“Sodium-(potassium)-chloride cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC12A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Furosemiderule | Boehringer Ingelheim | phase 4 | 27 |
Studies
All 2 Hikma Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00602615Edema · United States | – | Completed | Sep 2003 | 28 |
| NCT00602303Edema · United States | – | Completed | Sep 2003 | 28 |
How it is read
Names in the registry
- “Torsemide”, 4 entries
- “Torasemide tablet 10 mg”, 2 entries
- “torasemide”, 2 entries
- “torsemide”, 1 entry
- “CHF Patients: ER Torsemide 40 mg”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 2 studies
- Edema, 2 studies
- Body Weight Changes, 1 study
- Hypertension, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.